3-descladinosyl-11,12-dideoxy-6-O-methyl-12,11-(oxycarbonyl-(1-benzhydryl-azetidin-3-yl)-imino)-erythromycin | 893565-92-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-descladinosyl-11,12-dideoxy-6-O-methyl-12,11-(oxycarbonyl-(1-benzhydryl-azetidin-3-yl)-imino)-erythromycin
• 英文别名: [(2S,3R,4S,6R)-2-[[(1S,2R,5R,6S,7S,8R,9R,11R,13R,14R)-15-(1-benzhydrylazetidin-3-yl)-2-ethyl-6-hydroxy-9-methoxy-1,5,7,9,11,13-hexamethyl-4,12,16-trioxo-3,17-dioxa-15-azabicyclo[12.3.0]heptadecan-8-yl]oxy]-4-(dimethylamino)-6-methyloxan-3-yl] acetate
• CAS: 893565-92-9
• 化学式: C₄₉H₇₁N₃O₁₁
• 分子量: 878.116
• InChiKey: MTAVMQOBVQWTBH-PFOICZQJSA-N

物化性质

• 沸点：
  904.6±65.0 °C(Predicted)
• 密度：
  1.21±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6.4
• 重原子数：
  63
• 可旋转键数：
  11
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  154
• 氢给体数：
  1
• 氢受体数：
  13

反应信息

• 作为反应物：
  描述：

  3-descladinosyl-11,12-dideoxy-6-O-methyl-12,11-(oxycarbonyl-(1-benzhydryl-azetidin-3-yl)-imino)-erythromycin 在 盐酸 、 甲醇 、 N-氯代丁二酰亚胺 、 二甲基硫 、 20 % Pd(OH)2/C 、 三乙酰氧基硼氢化钠 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 水 、 乙酸乙酯 、 乙腈 为溶剂， 反应 42.0h， 生成 3-descladinosyl-11,12-dideoxy-6-O-methyl-3-oxo-12,11-(oxycarbonyl-(1-((3-hydroxy-[1,5]naphthyridin-4-yl)-methyl)-azetidin-3-yl)-imino)-erythromycin A
  参考文献：
  名称：

  Process Development of a Novel Azetidinyl Ketolide Antibiotic

  摘要：

  Process development and the multikilogram synthesis of a novel azetidinyl ketolide antibiotic is described. Starting with clarithromycin, the eight-step synthesis features several telescoped operations and direct isolations, which results in a significant improvement in throughput and a major reduction in solvent usage and waste stream volume over the first scale-up campaign. Particular highlights of this effort include the development of an efficient synthesis of 3-hydroxy-1,5-naphthyridine-4-carbaldehyde via a Skraup process and engineering a robust final API synthesis. We also discovered a crystalline monotosylate salt that addressed significant formulation and degradation issues experienced when using the noncrystalline freebase.

  DOI：

  10.1021/op300064b
• 作为产物：
  描述：

  克拉霉素 在 盐酸 、 4-二甲氨基吡啶 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 三乙胺 作用下， 以 四氢呋喃 、 水 、 乙腈 为溶剂， 反应 50.0h， 生成 3-descladinosyl-11,12-dideoxy-6-O-methyl-12,11-(oxycarbonyl-(1-benzhydryl-azetidin-3-yl)-imino)-erythromycin
  参考文献：
  名称：

  Process Development of a Novel Azetidinyl Ketolide Antibiotic

  摘要：

  Process development and the multikilogram synthesis of a novel azetidinyl ketolide antibiotic is described. Starting with clarithromycin, the eight-step synthesis features several telescoped operations and direct isolations, which results in a significant improvement in throughput and a major reduction in solvent usage and waste stream volume over the first scale-up campaign. Particular highlights of this effort include the development of an efficient synthesis of 3-hydroxy-1,5-naphthyridine-4-carbaldehyde via a Skraup process and engineering a robust final API synthesis. We also discovered a crystalline monotosylate salt that addressed significant formulation and degradation issues experienced when using the noncrystalline freebase.

  DOI：

  10.1021/op300064b

文献信息

• Macrolides
  申请人：Chupak S. Louis

  公开号：US20060135447A1

  公开（公告）日：2006-06-22

  Macrolide compounds per se, as shown below and defined herein, and their use, e.g., as antibacterial and antiprotozoal agents in animals, including humans: Also disclosed are methods of preparing the compounds, intermediates, and pharmaceutical compositions thereof, and methods of treating or preventing disease by administering the compounds to subjects in need. This abstract is only an excerpt and is not limiting of the invention.

  本发明涉及以下Macrolide化合物及其定义，以及它们在动物中，包括人类中作为抗菌和抗原虫剂的用途：还公开了制备这些化合物、中间体和药物组成物的方法，以及通过将这些化合物用于需要的主体治疗或预防疾病的方法。此摘要仅为摘录，不限制本发明。